Drug intelligence / Profile preview

RS-0735

Development stage: Preclinical
Modality: Small Molecules

Overview

RS-0735 is a small molecule drug candidate developed by RS Research Co. Ltd., currently in preclinical development. The specific molecular target and mechanism of action have not been publicly disclosed, but it is being investigated for oncology indications, particularly pancreatic cancer. The drug is part of the Sagitta Bir platform, which suggests a focus on targeted therapies or smart delivery systems in oncology. Its primary therapeutic areas include neoplasms (cancers), digestive system disorders, and endocrinology/metabolic diseases[1][2][4].

Beyond the preview

Go deeper on RS-0735.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS-0735.

Explore the full profile